<?xml version="1.0" encoding="UTF-8"?>
<p id="para160">The study vaccine GLS-5300 was manufactured at VGXI (The Woodlands, TX, USA) according to good manufacturing practices. GLS-5300 contains 6 mg/mL of plasmid pGX9101 in sterile water for injection. Plasmid pGX9101 contains a gene insert designed as an optimised, full-length, microconsensus of the MERS coronavirus S-glycoprotein generated from publicly available clinical sequences up to August 2015.
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref>
</p>
